JAGX
Income statement / Annual
Last year (2024), Jaguar Health, Inc.'s total revenue was $11.69 M,
an increase of 19.75% from the previous year.
In 2024, Jaguar Health, Inc.'s net income was -$38.49 M.
See Jaguar Health, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$11.69 M |
$9.76 M |
$11.96 M |
$4.34 M |
$9.39 M |
$5.78 M |
$4.42 M |
$4.36 M |
$141,523.00 |
$258,381.00 |
| Cost of Revenue |
$1.96 M
|
$2.04 M
|
$2.02 M
|
$2.33 M
|
$3.28 M
|
$3.82 M
|
$2.77 M
|
$880,405.00
|
$51,966.00
|
$123,457.00
|
| Gross Profit |
$9.73 M
|
$7.72 M
|
$9.94 M
|
$2.00 M
|
$6.11 M
|
$1.96 M
|
$1.65 M
|
$3.48 M
|
$89,557.00
|
$134,924.00
|
| Gross Profit Ratio |
0.83
|
0.79
|
0.83
|
0.46
|
0.65
|
0.34
|
0.37
|
0.8
|
0.63
|
0.52
|
| Research and Development Expenses |
$16.54 M
|
$18.60 M
|
$17.65 M
|
$15.08 M
|
$6.41 M
|
$5.82 M
|
$5.15 M
|
$4.27 M
|
$7.21 M
|
$6.48 M
|
| General & Administrative Expenses |
$16.33 M
|
$16.59 M
|
$17.87 M
|
$17.10 M
|
$14.39 M
|
$13.50 M
|
$12.28 M
|
$11.25 M
|
$5.98 M
|
$5.34 M
|
| Selling & Marketing Expenses |
$7.69 M
|
$6.46 M
|
$8.84 M
|
$8.89 M
|
$6.61 M
|
$6.94 M
|
$9.83 M
|
$3.08 M
|
$485,440.00
|
$765,091.00
|
| Selling, General & Administrative Expenses |
$24.02 M
|
$23.05 M
|
$26.71 M
|
$26.00 M
|
$21.00 M
|
$20.44 M
|
$22.11 M
|
$14.33 M
|
$6.47 M
|
$6.10 M
|
| Other Expenses |
$0.00
|
$371,000.00
|
$950,000.00
|
-$765,000.00
|
$190,000.00
|
$648,800.00
|
$315,691.00
|
$88,549.00
|
-$11,046.00
|
-$27,277.00
|
| Operating Expenses |
$40.57 M
|
$42.02 M
|
$44.35 M
|
$41.08 M
|
$27.41 M
|
$26.91 M
|
$27.26 M
|
$18.60 M
|
$13.68 M
|
$12.58 M
|
| Cost And Expenses |
$42.52 M
|
$44.05 M
|
$46.37 M
|
$43.41 M
|
$30.69 M
|
$30.72 M
|
$30.03 M
|
$19.48 M
|
$13.73 M
|
$12.70 M
|
| Interest Income |
$0.00
|
$0.00
|
$12.72 M
|
$8.42 M
|
$2.79 M
|
$5.73 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$231,000.00
|
$6.38 M
|
$12.72 M
|
$8.42 M
|
$2.79 M
|
$5.73 M
|
$2.63 M
|
$1.21 M
|
$985,549.00
|
$3.32 M
|
| Depreciation & Amortization |
$2.36 M
|
$1.16 M
|
$2.29 M
|
$1.83 M
|
$2.28 M
|
$1.93 M
|
$1.75 M
|
$584,339.00
|
$47,494.00
|
$5,155.00
|
| EBITDA |
-$36.66 M |
-$33.13 M |
-$33.38 M |
-$42.35 M |
-$28.74 M |
-$30.87 M |
-$27.77 M |
-$11.13 M |
-$13.70 M |
-$12.97 M |
| EBITDA Ratio |
-3.14
|
-3.39
|
-2.79
|
-9.77
|
-3.06
|
-5.35
|
-6.29
|
-2.55
|
-96.81
|
-50.19
|
| Operating Income Ratio |
-2.64
|
-3.51
|
-2.88
|
-9.01
|
-2.27
|
-4.32
|
-6.98
|
-7.85
|
-96
|
-48.17
|
| Total Other Income/Expenses Net |
-$8.42 M
|
-$7.61 M
|
-$13.98 M
|
-$11.89 M
|
-$7.16 M
|
-$9.58 M
|
-$1.32 M
|
-$902,796.00
|
-$1.15 M
|
-$3.85 M
|
| Income Before Tax |
-$39.25 M
|
-$41.90 M
|
-$48.40 M
|
-$52.60 M
|
-$33.81 M
|
-$38.53 M
|
-$32.15 M
|
-$35.15 M
|
-$14.73 M
|
-$16.29 M
|
| Income Before Tax Ratio |
-3.36
|
-4.29
|
-4.05
|
-12.13
|
-3.6
|
-6.67
|
-7.28
|
-8.06
|
-104.11
|
-63.05
|
| Income Tax Expense |
-$759,000.00
|
$0.00
|
-$941,000.00
|
$7.65 M
|
$2.98 M
|
$10,000.00
|
-$1.28 M
|
-$13.18 M
|
$1.14 M
|
$3.82 M
|
| Net Income |
-$38.49 M
|
-$41.30 M
|
-$47.45 M
|
-$60.25 M
|
-$36.79 M
|
-$38.54 M
|
-$32.15 M
|
-$21.97 M
|
-$14.73 M
|
-$16.29 M
|
| Net Income Ratio |
-3.29
|
-4.23
|
-3.97
|
-13.9
|
-3.92
|
-6.67
|
-7.28
|
-5.04
|
-104.11
|
-63.05
|
| EPS |
-130.69 |
-2685 |
-4070250 |
-11370375 |
-72299250 |
-589406625 |
-366353347500 |
-9658965487500 |
-88496325225000 |
-169803473175000 |
| EPS Diluted |
-130.69 |
-2685 |
-4070250 |
-11370375 |
-72299250 |
-589406625 |
-366353347500 |
-9658965487500 |
-88496325225000 |
-169803473175000 |
| Weighted Average Shares Out |
$294,534.00
|
$15,421.00
|
$11.69
|
$5.31
|
$0.51
|
$0.07
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$294,534.00
|
$15,421.00
|
$11.69
|
$5.31
|
$0.51
|
$0.07
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
